BACKGROUND: In light of accumulated scientific evidence of the secondary preventive benefits of antiretroviral therapy, a growing number of jurisdictions worldwide have formally started to implement HIV Treatment as Prevention (TasP) programs. To date, no gold standard for TasP program monitoring has been described. Here, we describe the design and methods applied to TasP program process monitoring in British Columbia (BC), Canada. METHODS: Monitoring indicators were selected through a collaborative and iterative process by an interdisciplinary team including representatives from all 5 regional health authorities, the BC Centre for Disease Control (BCCDC), and the BC Centre for Excellence in HIV/AIDS (BC-CfE). An initial set of 36 proposed indicators were considered for inclusion. These were ranked on the basis of 8 criteria: data quality, validity, scientific evidence, informative power of the indicator, feasibility, confidentiality, accuracy, and administrative requirement. The consolidated list of indicators was included in the final monitoring report, which was executed using linked population-level data. RESULTS: A total of 13 monitoring indicators were included in the BC TasP Monitoring Report. Where appropriate, indicators were stratified by subgroups of interest, including HIV risk group and demographic characteristics. Six Monitoring Reports are generated quarterly: 1 for each of the regional health authorities and a consolidated provincial report. CONCLUSIONS: We have developed a comprehensive TasP process monitoring strategy using evidence-based HIV indicators derived from linked population-level data. Standardized longitudinal monitoring of TasP program initiatives is essential to optimize individual and public health outcomes and to enhance program efficiencies.
BACKGROUND: In light of accumulated scientific evidence of the secondary preventive benefits of antiretroviral therapy, a growing number of jurisdictions worldwide have formally started to implement HIV Treatment as Prevention (TasP) programs. To date, no gold standard for TasP program monitoring has been described. Here, we describe the design and methods applied to TasP program process monitoring in British Columbia (BC), Canada. METHODS: Monitoring indicators were selected through a collaborative and iterative process by an interdisciplinary team including representatives from all 5 regional health authorities, the BC Centre for Disease Control (BCCDC), and the BC Centre for Excellence in HIV/AIDS (BC-CfE). An initial set of 36 proposed indicators were considered for inclusion. These were ranked on the basis of 8 criteria: data quality, validity, scientific evidence, informative power of the indicator, feasibility, confidentiality, accuracy, and administrative requirement. The consolidated list of indicators was included in the final monitoring report, which was executed using linked population-level data. RESULTS: A total of 13 monitoring indicators were included in the BC TasP Monitoring Report. Where appropriate, indicators were stratified by subgroups of interest, including HIV risk group and demographic characteristics. Six Monitoring Reports are generated quarterly: 1 for each of the regional health authorities and a consolidated provincial report. CONCLUSIONS: We have developed a comprehensive TasP process monitoring strategy using evidence-based HIV indicators derived from linked population-level data. Standardized longitudinal monitoring of TasP program initiatives is essential to optimize individual and public health outcomes and to enhance program efficiencies.
Authors: C C Carpenter; M A Fischl; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Sáag; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding Journal: JAMA Date: 1996-07-10 Impact factor: 56.272
Authors: Viviane D Lima; Richard Harrigan; Melanie Murray; David M Moore; Evan Wood; Robert S Hogg; Julio Sg Montaner Journal: AIDS Date: 2008-11-12 Impact factor: 4.177
Authors: Viviane D Lima; Richard Harrigan; David R Bangsberg; Robert S Hogg; Robert Gross; Benita Yip; Julio S G Montaner Journal: J Acquir Immune Defic Syndr Date: 2009-04-15 Impact factor: 3.731
Authors: Evan Wood; Thomas Kerr; Brandon D L Marshall; Kathy Li; Ruth Zhang; Robert S Hogg; P Richard Harrigan; Julio S G Montaner Journal: BMJ Date: 2009-04-30
Authors: Viviane D Lima; Lillian Lourenço; Benita Yip; Robert S Hogg; Peter Phillips; Julio S G Montaner Journal: Lancet HIV Date: 2015-03 Impact factor: 12.767
Authors: S Y Lin; N J Lachowsky; M Hull; A Rich; Z Cui; P Sereda; J Jollimore; K Stephenson; M Thumath; Jsg Montaner; E A Roth; R S Hogg; D M Moore Journal: HIV Med Date: 2016-08-01 Impact factor: 3.180
Authors: Benjamin J Klassen; Nathan J Lachowsky; Sally Yue Lin; Joshua B Edward; Sarah A Chown; Robert S Hogg; David M Moore; Eric A Roth Journal: Qual Health Res Date: 2017-07-01
Authors: Nathan J Lachowsky; Sally Y Lin; Mark W Hull; Zishan Cui; Paul Sereda; Jody Jollimore; Ashleigh Rich; Julio S G Montaner; Eric A Roth; Robert S Hogg; David M Moore Journal: AIDS Behav Date: 2016-07
Authors: Michelle Olding; Ben Enns; Dimitra Panagiotoglou; Jean Shoveller; P Richard Harrigan; Rolando Barrios; Thomas Kerr; Julio S G Montaner; Bohdan Nosyk Journal: J Int AIDS Soc Date: 2017-09-19 Impact factor: 5.396
Authors: Allison Carter; Nathan Lachowsky; Ashleigh Rich; Jamie I Forrest; Paul Sereda; Zishan Cui; Eric Roth; Angela Kaida; David Moore; Julio Sg Montaner; Robert S Hogg Journal: J Int AIDS Soc Date: 2015-08-11 Impact factor: 5.396